Study on the application of atorvastatin and rosuvastatin in the treatment of coronary heart disease
冠心病治疗中的阿托伐他汀和瑞舒伐他汀应用研究

摘要

目的 分析冠心病治疗中分别使用阿托伐他汀和瑞舒伐他汀体现的临床效果。方法 择取本院医治共106例冠心病患者（时间2023年1月至2024年1月），将其均分2组，每组53例。2组均接受常规基础治疗，同时对照组予以阿托伐他汀，观察组予以瑞舒伐他汀。评比2组临床效果、心功能、血脂指标。结果 观察组临床总有效率与对照组比较存在提高，统计学分析存在差异（P＜0.05）。治疗后观察组左室射血分数（LVEF）、心排血量（CO）相比对照组升高，统计学分析存在差异（P＜0.05）。治疗后观察组三酰甘油（TG）、总胆固醇（TC）相比对照组下降，统计学分析存在差异（P＜0.05）。结论 冠心病治疗中瑞舒伐他汀相比阿托伐他汀的临床效果更好，可有效降低血脂，促进心功能改善。

Abstract

Objective To analyze the clinical effects of atorvastatin and rosuvastatin respectively in the treatment of coronary heart disease.
Methods A total of 106 patients with coronary heart disease (from January 2023 to January 2024) were selected from our hospital and divided into 2 groups with 53 cases in each group. Both groups received conventional basic treatment, while the control group was given atorvastatin and the observation group was given rosuvastatin. The clinical effect, heart function and blood lipid indexes of the two groups were evaluated.
Results The total effective rate of the observation group was higher than that of the control group (P < 0.05). After treatment, the left ventricular ejection fraction (LVEF) and cardiac output (CO) of the observation group were higher than those of the control group, and the differences were statistically significant (P < 0.05). After treatment, triglyceride (TG) and total cholesterol (TC) in the observation group were decreased compared with that in the control group, and there were differences in statistical analysis (P < 0.05).
Conclusion   Rosuvastatin has better clinical effect than atorvastatin in the treatment of coronary heart disease, which can effectively reduce blood lipids and promote the improvement of cardiac function.